UroGen Pharma Ltd. (URGN) Cash Flow Statement
UroGen Pharma Ltd. (URGN) generated -$158.9M of operating cash flow over the twelve months to 2026-06-30, spent $218000 on capital expenditure and had free cash flow of -$159.1M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
URGNUroGen Pharma Ltd.Follow URGN — free
—
Price chart with a free account
- Market cap
- 1.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -9.6 | -37.3 | -71.0 | -105.9 | -84.9 | -87.6 | -76.4 | -96.8 | -162.4 | -158.9 | |
| Capital expenditure | 0.3 | 0.6 | 0.3 | 1.2 | 0.8 | 0.3 | 0.2 | 0.3 | 0.3 | -0.2 | |
| Free cash flow | -9.8 | -37.9 | -71.3 | -107.1 | -85.6 | -87.8 | -76.6 | -97.1 | -162.7 | -159.1 | |
| Stock-based compensation | 6.3 | 30.6 | 30.0 | 28.0 | 23.1 | 10.6 | 9.3 | 13.1 | 12.0 | — |
USD millions · SEC XBRL
UroGen Pharma Ltd. — questions
- What is UroGen Pharma Ltd.'s operating cash flow?
- -$158.9M over the twelve months to 2026-06-30.
- How much does UroGen Pharma Ltd. spend on capital expenditure?
- $218000 over the twelve months to 2026-06-30.
- What is UroGen Pharma Ltd.'s free cash flow?
- -$159.1M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from UroGen Pharma Ltd.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.